Your browser doesn't support javascript.
loading
Yifei Sanjie Formula or Placebo With Anlotinib as Second-Line or Above Treatment for Metastatic Non-Small-Cell Lung Cancer: Study Protocol for a Double-Blind, Placebo-Controlled Randomized Pilot Study.
Chen, Wenmin; Lin, Jietao; Yang, Ting; Xin Zhang, Ze; Tao, Lanting; Xiao, Zhiwei; Chen, Hanrui; Qi, Xiangjun; Sun, Lingling; Cao, Yang; Lin, Lizhu.
Afiliação
  • Chen W; Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Lin J; Guangzhou University of Traditional Chinese Medicine First Affiliated Hospital, Guangzhou, China.
  • Yang T; Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Xin Zhang Z; Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Tao L; Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Xiao Z; Guangzhou University of Traditional Chinese Medicine First Affiliated Hospital, Guangzhou, China.
  • Chen H; Guangzhou University of Traditional Chinese Medicine First Affiliated Hospital, Guangzhou, China.
  • Qi X; Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Sun L; Guangzhou University of Traditional Chinese Medicine First Affiliated Hospital, Guangzhou, China.
  • Cao Y; Guangzhou University of Traditional Chinese Medicine First Affiliated Hospital, Guangzhou, China.
  • Lin L; Guangzhou University of Traditional Chinese Medicine First Affiliated Hospital, Guangzhou, China.
Integr Cancer Ther ; 22: 15347354221151147, 2023.
Article em En | MEDLINE | ID: mdl-36710490

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Tipo de estudo: Clinical_trials / Guideline Limite: Humans Idioma: En Revista: Integr Cancer Ther Assunto da revista: NEOPLASIAS / TERAPEUTICA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Tipo de estudo: Clinical_trials / Guideline Limite: Humans Idioma: En Revista: Integr Cancer Ther Assunto da revista: NEOPLASIAS / TERAPEUTICA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China